TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15364220

Group type: EXPERIMENTAL
Intervention: Timolol (0.5% Timoptic‐XE)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005% Xalatan)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 18
Study: 11336101

Group type: EXPERIMENTAL
Intervention: Fluvastatin extended-release 80 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fluvastatin extended-release 160 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fluvastatin extended-release 320 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fluvastatin extended-release 640 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9601592

Group type: EXPERIMENTAL
Intervention: Bupivacaine gel (2.5 mg/ml)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketoprofen gel (1.6 mg/ml)
Number of subjects: 12
Study: 7978179

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study: 2492832

Group type: EXPERIMENTAL
Intervention: Immunoglobulin (IgG) therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1273209

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg delta9-tetrahydrocannabinol (THC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg delta9-tetrahydrocannabinol (THC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg delta9-tetrahydrocannabinol (THC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: delta9-tetrahydrocannabinol (THC)
Number of subjects: 20
Study: 30359204

Group type: EXPERIMENTAL
Intervention: Early, integrated palliative care (PC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual oncology care
Number of subjects: 19
Study: 28005621

Group type: EXPERIMENTAL
Intervention: Ram Relaxation Technique (RRT)
Number of subjects: 20
Study: 26278784

Group type: EXPERIMENTAL
Intervention: DIALOG+ intervention used once per month for 6 months
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: DIALOG+ intervention
Number of subjects: 179

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 179
Study: 24041518

Group type: EXPERIMENTAL
Intervention: New method of microskin autografting with a Vaseline-based moisture dressing
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional method of microskin autografting
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: New method of microskin autografting
Number of subjects: 52
Study: 21849285

Group type: EXPERIMENTAL
Intervention: 6 months of abacavir-lamivudine-zidovudine concurrent with tuberculosis therapy
Number of subjects: 214

Group type: COMPARATOR
Intervention: Delayed antiretroviral therapy
Number of subjects: 214
Study: 19437617

Group type: EXPERIMENTAL
Intervention: Topical phenylephrine 10% with intracameral lidocaine 1%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topical cyclopentolate 1% and phenylephrine 10% with intracameral lidocaine 1%
Number of subjects: 20
Study: 17666348

Group type: EXPERIMENTAL
Intervention: Tangshenqing (TSQ) combined with basic treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Alprostadil injections combined with TSQ and basic treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Basic treatment (control group)
Number of subjects: 120
Study: 15310631

Group type: COMPARATOR
Intervention: Normal saline 2 mL (Placebo)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg.kg(‐1)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Propofol 0.6 mg.kg(‐1)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Ephedrine 5 mg
Number of subjects: 118
Study: 11692217

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) treatment (high dose)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no NAC treatment)
Number of subjects: 19
Study: 9131324

Group type: EXPERIMENTAL
Intervention: Cefdinir 14 mg/kg once-daily
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Cefdinir 7 mg/kg b.i.d.
Number of subjects: 752

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 13.3 mg/kg t.i.d.
Number of subjects: 752
Study: 8176568

Group type: EXPERIMENTAL
Intervention: Spironolactone and chlorothiazide
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 2962954

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28989074

Group type: EXPERIMENTAL
Intervention: TAU plus active rehabilitation (in-clinic subsymptom threshold aerobic training, coordination exercises, visualization and imagery techniques with a physiotherapist, mean 3.4 sessions, over 6 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Active rehabilitation
Number of subjects: 19
Study: 26541230

Group type: EXPERIMENTAL
Intervention: Cementless total hip arthroplasty with intraoperative calcar fracture
Number of subjects: 2913

Group type: COMPARATOR
Intervention: Control group (no calcar fractures)
Number of subjects: 2913
Study: 25643864

Group type: EXPERIMENTAL
Intervention: Mind Reading and in vivo rehearsal treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 23663588

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 150
Study: 19775500

Group type: EXPERIMENTAL
Intervention: 600 mg of cannabidiol (CBD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg Delta 9‐tetrahydrocannabinol (Delta 9‐THC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 18403122

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (26.8 microg ED(50) in Group A, 17.7 microg ED(50) in Group G)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (27.4 microg ED(50) in Group A, 12.8 microg ED(50) in Group G)
Number of subjects: 224
Study: 16899804

Group type: EXPERIMENTAL
Intervention: Behavioral internet program
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 57
Study: 12660911

Group type: EXPERIMENTAL
Intervention: Randomized placebo-controlled trial of an injectable medicine given throughout pregnancy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Declining participation in the trial
Number of subjects: 50
Study: 14967373

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg p.o. t.i.d. for 6 months
Number of subjects: 29
Study: 10490154

Group type: EXPERIMENTAL
Intervention: 0.1 mg intrathecal morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.25 mg intrathecal morphine
Number of subjects: 60
Study: 7581719

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 micrograms b.i.d.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 50 micrograms b.i.d.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2379594

Group type: EXPERIMENTAL
Intervention: Metachronous metastases resection
Number of subjects: 122

Group type: COMPARATOR
Intervention: Synchronous metastases resection
Number of subjects: 122
Study: 205382

Group type: EXPERIMENTAL
Intervention: Calcitriol (1,25(OH)2D3) at a mean dose of 0.579 microgram/day for 3 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vitamin D3 at a mean dose of 706 IU/day
Number of subjects: 22
Study: 31180926

Group type: EXPERIMENTAL
Intervention: Donor cornea with preservation time (PT) of 0 to 7 days (N = 675)
Number of subjects: 1330

Group type: COMPARATOR
Intervention: Donor cornea with preservation time (PT) of 8 to 14 days (N = 655)
Number of subjects: 1330
Study: 28577691

Group type: EXPERIMENTAL
Intervention: Complete revascularization at index admission
Number of subjects: 296

Group type: COMPARATOR
Intervention: IRA-only P-PCI
Number of subjects: 296
Study: 25881046

Group type: EXPERIMENTAL
Intervention: Azithromycin plus Chloroquine (AZCQ)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 255
Study: 24072504

Group type: EXPERIMENTAL
Intervention: Acute dietary tryptophan depletion (ATD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tryptophan-balanced amino acid load (BAL)
Number of subjects: 18
Study: 21857969

Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention in a randomized clinical trial of pharmaceutical care
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-adherent patients (n=12)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Adherent patients (n=44)
Number of subjects: 56
Study: 19752847

Group type: EXPERIMENTAL
Intervention: Interactive music with conscious sedation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group with sedation
Number of subjects: 39
Study: 17095420

Group type: EXPERIMENTAL
Intervention: Smooth Move (n = 42)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 86
Study: 14747881

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg o.d.
Number of subjects: 144

Group type: COMPARATOR
Intervention: Enalapril 20 mg o.d.
Number of subjects: 144
Study: 11320181

Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9219204

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg BID (beta 1-antagonist)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg BID (combined beta 1, beta 2-antagonist)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atenolol and Propranolol
Number of subjects: 7
Study: 7957426

Group type: COMPARATOR
Intervention: IVGG therapy
Number of subjects: 79

Group type: COMPARATOR
Intervention: Low-dose PTX and IVGG combination therapy (10 mg/kg per day)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: High-dose PTX and IVGG combination therapy (20 mg/kg per day)
Number of subjects: 79
Study: 31150295

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy for Adolescents (PE-A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Client-Centered Therapy (CCT)
Number of subjects: 61
Study: 30389037

Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise training (three 45-min sessions per week for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no lifestyle changes)
Number of subjects: 40
Study: 26171942

Group type: COMPARATOR
Intervention: Blood self-monitoring
Number of subjects: 181

Group type: COMPARATOR
Intervention: Urine self-monitoring
Number of subjects: 181
Study: 24552319

Group type: EXPERIMENTAL
Intervention: Hydrocortisone-bacitracin-colistin eardrops
Number of subjects: 230

Group type: COMPARATOR
Intervention: Oral amoxicillin-clavulanate suspension
Number of subjects: 230

Group type: COMPARATOR
Intervention: Initial observation
Number of subjects: 230
Study: 23856594

Group type: EXPERIMENTAL
Intervention: Recovery coach for substance-involved mothers
Number of subjects: 453

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 453
Study: 18955324

Group type: EXPERIMENTAL
Intervention: Satureja khuzestanica (250 mg dried leaves, once a day for 60 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 18853287

Group type: EXPERIMENTAL
Intervention: Audiovisual distraction (watching cartoon films)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (without any intervention)
Number of subjects: 300
Study: 16883452

Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 75

Group type: COMPARATOR
Intervention: 0.125% bupivacaine plus neostigmine 4 ug kg‐1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine plus 1 ug kg‐1 fentanyl
Number of subjects: 75
Study: 12680791

Group type: EXPERIMENTAL
Intervention: Adjuvant whole brain radiation therapy (WBRT) with focal treatment (stereotactic radiosurgery or conventional surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Focal treatment (stereotactic radiosurgery or conventional surgery)
Number of subjects: 0
Study: 11016001

Group type: EXPERIMENTAL
Intervention: Azasetron plus dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azasetron alone
Number of subjects: 0
Study: 8857326

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TNS)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 234
Study: 1621152

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: Anterior surgery
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: Kyphotic deformity greater than 30 degrees
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Seat belts
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Fracture type
Number of subjects: 1019
Study: 6546416

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin E (15 mg/kg on day 1, 10 mg/kg on days 2, 4, and 6)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Oral vitamin E (100 mg/kg/d)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo intramuscular injections
Number of subjects: 168
Study: 31374703

Group type: EXPERIMENTAL
Intervention: Visual distortion environment (robot-free, visual feedback)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29580213

Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 854

Group type: COMPARATOR
Intervention: Control writing task
Number of subjects: 854

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 854
Study: 26729760

Group type: EXPERIMENTAL
Intervention: IR dl‐MPH (0.3 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: IR d‐MPH (0.15 mg/kg)
Number of subjects: 24
Study: 25008878

Group type: EXPERIMENTAL
Intervention: Endotracheal lavage with porcine pulmonary surfactant (PS)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Intratracheal injection of porcine pulmonary surfactant (PS)
Number of subjects: 136
Study: 22569045

Group type: EXPERIMENTAL
Intervention: Topical lidocaine after Listerine mouthwash
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Topical lidocaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 120
Study: 19765953

Group type: EXPERIMENTAL
Intervention: 1000 mg/d of calcium intake during bedrest (study A)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 2000 mg/d of calcium intake during bedrest (study B)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ambulatory control phase (for both studies)
Number of subjects: 17
Study: 18808597

Group type: EXPERIMENTAL
Intervention: Home-based nurse assessment of falls-and-fracture risk factors and home hazards, referral to appropriate community interventions, and strength and balance exercise program
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care and social visits
Number of subjects: 312
Study: 16022169

Group type: EXPERIMENTAL
Intervention: Experimental treatments (multiple)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 0
Study: 12383065

Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 0
Study: 10439731

Group type: EXPERIMENTAL
Intervention: Sevoflurane (2% plus 67% nitrous oxide)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isoflurane (1.2% plus 67% nitrous oxide)
Number of subjects: 24
Study: 7557866

Group type: EXPERIMENTAL
Intervention: UDCA/MTX (Ursodeoxycholic acid 13 to 15 mg/kg/d and Methotrexate 0.25 mg/kg/wk)
Number of subjects: 32

Group type: COMPARATOR
Intervention: UDCA alone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 32
Study: 2265237

Group type: EXPERIMENTAL
Intervention: 75 mg PPA HCl CR caplet once daily for 4 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: 25 mg PPA HCl solution three times a day for 4 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 12
Study: 388402

Group type: EXPERIMENTAL
Intervention: Tienilic acid 250 mg once and twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg once and twice daily
Number of subjects: 0
Study: 31470813

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia with ropivacaine wound infiltration and intravenous flurbiprofen axetil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 40
Study: 30030717

Group type: EXPERIMENTAL
Intervention: Laparoscopic 270 degree posterior fundoplication (LTF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laparoscopic 180 degree anterior fundoplication (LAF)
Number of subjects: 20
Study: 27001081

Group type: EXPERIMENTAL
Intervention: 0.8 FiO2 (80% oxygen concentration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.4 FiO2 (40% oxygen concentration)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 25266438

Group type: EXPERIMENTAL
Intervention: Eszopiclone (1 or 2 mg for ages 6-11 years; 2 or 3 mg for ages 12-17 years)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 486
Study: 22917728

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon plus bare metal stent (DCB/BMS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (DES)
Number of subjects: 55
Study: 20184226

Group type: EXPERIMENTAL
Intervention: Pantoprazole formulations in biorelevant medium using USP apparatus 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pantoprazole formulations in biorelevant medium using USP apparatus 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro dissolution profiles
Number of subjects: 0
Study: 18042869

Group type: EXPERIMENTAL
Intervention: Injection-infusion with levobupivacaine
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo injection-infusion
Number of subjects: 154
Study: 17130031

Group type: EXPERIMENTAL
Intervention: Group A (n = 38) received 1 g paracetamol and 100 mg diclofenac
Number of subjects: 74

Group type: COMPARATOR
Intervention: Group B (n = 36) received 1 g paracetamol only
Number of subjects: 74
Study: 14595274

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 microg once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Budesonide 200 microg twice daily
Number of subjects: 24
Study: 10335995

Group type: EXPERIMENTAL
Intervention: Oral iron (3 x 100 mg Fe2+ per day for 5 weeks before operation)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intravenous iron (200 mg Fe3+ after each donation with initial i.v. iron supplementation for hemoglobin under 15 g/dL)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no iron medication)
Number of subjects: 123
Study: 8565027

Group type: EXPERIMENTAL
Intervention: BDP AQ Forte (0.084%) nasal spray 336 micrograms once daily
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: BDP AQ (0.042%) nasal spray 168 micrograms twice daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo nasal spray twice daily
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Oral prednisone 10 mg once daily in the morning
Number of subjects: 64
Study: 1687999

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6750252

Group type: EXPERIMENTAL
Intervention: 1000 rad total body irradiation (TBI) in a single exposure
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1200 rad TBI fractionated over six days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All patients transplanted in second remission
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Patients transplanted in second remission
Number of subjects: 24

Group type: COMPARATOR
Intervention: Patients transplanted in relapse
Number of subjects: 24
Study: 31876665

Group type: EXPERIMENTAL
Intervention: Self-reported total physical activity (PA)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Watching television
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Physical activity and sedentary behavior
Number of subjects: 103
Study: 30808365

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0
Study: 29738177

Group type: EXPERIMENTAL
Intervention: Microscopic spermatic vein ligation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional open high ligation
Number of subjects: 120
Study: 25931216

Group type: EXPERIMENTAL
Intervention: Stopping immunosuppressive agents (SD group)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (did not stop immunosuppressive drugs)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Patients who survived pulmonary infection (both groups)
Number of subjects: 104
Study: 23333785

Group type: EXPERIMENTAL
Intervention: 100% oxygen (O2 group; n = 14)
Number of subjects: 85

Group type: COMPARATOR
Intervention: air group (control; n = 40)
Number of subjects: 85
Study: 21415171

Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD; 55-60E% fat, 25-30E% carbohydrate, and 15E% protein)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal diet (ND; 25-35E% fat, 55-60E% carbohydrate, and 10-15E% protein)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD) with lipid substrate (octanoyl-carnitine with or without ADP)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD)
Number of subjects: 21
Study: 19546869

Group type: EXPERIMENTAL
Intervention: Hunger condition (Study 1)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Hunger condition (Study 2)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Sated condition (Study 1)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Sated condition (Study 2)
Number of subjects: 151